DCAT Value Chain Insights’ Production to Prescription
DCAT
DCAT Value Chain Insights' Production to Prescription podcast, presented by the Drug, Chemical & Associated Technologies Association (DCAT), features thought leaders with expert views on the major happenings impacting the global bio/pharmaceutical manufacturing value chain and industry performance.
All episodes
Best episodes
Top 10 DCAT Value Chain Insights’ Production to Prescription Episodes
Goodpods has curated a list of the 10 best DCAT Value Chain Insights’ Production to Prescription episodes, ranked by the number of listens and likes each episode have garnered from our listeners. If you are listening to DCAT Value Chain Insights’ Production to Prescription for the first time, there's no better place to start than with one of these standout episodes. If you are a fan of the show, vote for your favorite DCAT Value Chain Insights’ Production to Prescription episode by adding your comments to the episode page.
Re-configuring Global Pharma Supply Chains
DCAT Value Chain Insights’ Production to Prescription
07/10/20 • 17 min
In this podcast we feature an article that looks at the policy debate to repatriate and increase domestic drug manufacturing in the US in light of the COVID-19 pandemic and pharmaceutical supply-chain vulnerabilities. For a text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- A plan for addressing supply-chain vulnerabilities in the US
- Legislative proposals in the US
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
2020 Vision: Digital Pharma—Beyond the Pill
DCAT Value Chain Insights’ Production to Prescription
06/29/20 • 10 min
In this podcast we feature an article that explores the future of digital medicines. For a text version of this article, visit dcatvci.org.
Key topics: (see Chapter Markers)
- Digital medicines and digital health
- Digital health and digital medicines: a market view
- Pharma industry and digital health and digital medicines
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
CDMOs Step Up to the COVID Challenge but Must Prepare for Uncertain Future
DCAT Value Chain Insights’ Production to Prescription
06/11/20 • 12 min
In this podcast we feature an article that looks at the near-term and long-term impact of the COVID-19 pandemic as biopharma companies re-access drug-development projects. For a text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- The CDMO industry in the wake of COVID-19
- Near-term outlook
- Medium-term could be challenging
- Longer-term implications
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
DCAT Benchmarking Study Provides Insight into Supply-Chain Challenges
DCAT Value Chain Insights’ Production to Prescription
05/28/20 • 14 min
In this podcast, we feature an article about a recent DCAT Benchmarking study, conducted prior to COVID-19, that provides insights on whether biopharma companies and their suppliers believe the deteriorating trade environment is a major threat, and what they are doing to confront the real and potential risks to their supply chains. For a text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- Examining trade-related risks
- Study's background
- Sources of supply-chain risk
- Awareness of supply-chain risk
- Managing supply-chain risks
- US market scenarios
- Vulnerable industry supply chains
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Bio/Pharma Industry Outlook, Supply Chains 2025: The Year Ahead
DCAT Value Chain Insights’ Production to Prescription
12/30/24 • 24 min
What will be the key issues shaping bio/pharma supply chains in 2025? Looking at the impact of potential changes in US tariff and trade policy. Plus, what lies ahead in product-specific supply chains for sterile injectables and antibody drug conjugates. And the latest on how companies are advancing upstream supplier risk monitoring and predictive risk planning, including through digitalization and AI.
Featuring: Derron Stark, EY-Parthenon Partner, Strategy & Transactions – Health Sciences & Wellness, Supply Chain, Ernst & Young LLP
The CDMO/CMO Report: Parenteral Drugs
DCAT Value Chain Insights’ Production to Prescription
11/16/22 • 30 min
Increased demand in biologic-based drug development is a key factor driving demand for parenteral drug manufacturing. What are key trends and expansions by CDMO/CMOs in parenteral drug manufacturing? DCAT Value Chain Insights rounds up the latest developments among CDMO/CMOs. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers in drop down menu in audio player above)
- Recent expansion projects
- Baxter BioPharma Solutions
- Vetter
- Recipharm
- WuXi STA
- Jubilant HollisterStier
- PCI Pharma Services
- Grand River Aseptic Manufacturing
- Catalent
- Thermo Fisher Scientific
- Lonza
- Carbogen Amcis
- Alcami
- Delpharm
- Fareva
- WuXi Biologics
- IDT Biologika
- Emergent CDMO
- BSP Pharmaceuticals
- Aenova
- Samsung Biologics
- Ajinomoto Bio-Pharma Services
- Selkirk Pharma
- INCOG BioPharma Services
- ten23 health
- Berkshire Sterile Manufacturing
Sponsor: Vetter Pharma International GmbH
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Company on the Move: Viatris
DCAT Value Chain Insights’ Production to Prescription
11/20/20 • 13 min
In this podcast we feature an article about what and who is behind Viatris, the new company formed from the combination of Upjohn, Pfizer’s off-patent branded and generic established medicines business, and Mylan. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- Rationale for the new company
- Inside the new Viatris: products
- Inside the new Viatris: manufacturing
- Inside Viatris: leadership, company structure, and cost-savings plan
Sponsor: LabVantage Solutions
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Top 10 Watch List: Pharma CEOs on the Rise
DCAT Value Chain Insights’ Production to Prescription
10/23/20 • 18 min
In this podcast we feature a list of the Top 10 pharma CEOs to watch in 2020. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- Pharma CEOs to watch in 2020
- 1. Three-way tie: Pfizer, J&J, and AstraZeneca.
- Pfizer Chairman and CEO Albert Bourla
- J&J Chairman and CEO Alex Gorsky
- AstraZeneca CEO Pascal Soriot
- 4. Moderna CEO Stéphane Bancel
- 5. Gilead Sciences Chairman and CEO Daniel O’Day
- 6. Regeneron Pharmaceuticals Co-Founder, President and CEO Leonard S. Schleifer
- 7 (tie). CureVac CEO Franz-Werner Haas and Novavax CEO and President Stanley C. Erck
- 9. Seagen (formerly Seattle Genetics) President, CEO and Chairman Clay Siegall
- 10. Genmab CEO Jan G. J. van de Winkel
Sponsor: LabVantage Solutions
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
Novel Excipients: Gaining Traction in the Industry
DCAT Value Chain Insights’ Production to Prescription
08/10/20 • 20 min
In this podcast we feature an article that outlines the FDA’s proposed pilot program for the evaluation of novel excipients and summarizes industry feedback on the review program. For a text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
Novel excipients and the FDA
FDA’s view of a possible novel excipient review pilot program
Industry feedback
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Sponsor: LabVantage Solutions
The Pipeline Contenders: What Drugs Are Making the Mark?
DCAT Value Chain Insights’ Production to Prescription
10/09/20 • 12 min
In this podcast we feature an article that looks at some key upcoming developments from the pipelines of the large pharmaceutical companies for new drugs or existing drugs with new indications with blockbuster potential. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- Inside Big Pharma’s pipeline
- AbbVie
- Amgen/AstraZeneca
- AstraZeneca
- Bristol-Myers Squibb
- Eli Lilly and Company
- GlaxoSmithKline
- Roche
Sponsor: Vetter Pharma International GmbH
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
Show more best episodes
Show more best episodes
FAQ
How many episodes does DCAT Value Chain Insights’ Production to Prescription have?
DCAT Value Chain Insights’ Production to Prescription currently has 48 episodes available.
What topics does DCAT Value Chain Insights’ Production to Prescription cover?
The podcast is about And, Development, Podcasts, Manufacturing, Science, Business and Pharmaceutical.
What is the most popular episode on DCAT Value Chain Insights’ Production to Prescription?
The episode title 'Bio/Pharma Industry Outlook, Supply Chains 2025: The Year Ahead' is the most popular.
What is the average episode length on DCAT Value Chain Insights’ Production to Prescription?
The average episode length on DCAT Value Chain Insights’ Production to Prescription is 18 minutes.
How often are episodes of DCAT Value Chain Insights’ Production to Prescription released?
Episodes of DCAT Value Chain Insights’ Production to Prescription are typically released every 14 days, 3 hours.
When was the first episode of DCAT Value Chain Insights’ Production to Prescription?
The first episode of DCAT Value Chain Insights’ Production to Prescription was released on Feb 14, 2020.
Show more FAQ
Show more FAQ